Cerity Partners LLC Has $11.89 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Cerity Partners LLC raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 102.4% in the fourth quarter, HoldingsChannel.com reports. The firm owned 146,740 shares of the biopharmaceutical company’s stock after purchasing an additional 74,249 shares during the quarter. Cerity Partners LLC’s holdings in Gilead Sciences were worth $11,888,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. PCA Investment Advisory Services Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,000. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Tompkins Financial Corp grew its position in shares of Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 241 shares during the period. Fortitude Family Office LLC acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $29,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the sale, the chief financial officer now directly owns 101,534 shares of the company’s stock, valued at approximately $8,709,586.52. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total value of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total value of $428,900.00. Following the completion of the sale, the chief financial officer now directly owns 101,534 shares of the company’s stock, valued at approximately $8,709,586.52. The disclosure for this sale can be found here. Insiders sold a total of 9,000 shares of company stock valued at $721,180 in the last ninety days. 0.16% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

GILD has been the subject of several recent analyst reports. Royal Bank of Canada reduced their price objective on shares of Gilead Sciences from $76.00 to $75.00 and set a “sector perform” rating for the company in a research report on Wednesday, February 14th. Oppenheimer cut their target price on Gilead Sciences from $115.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, February 12th. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and cut their target price for the stock from $91.00 to $82.00 in a report on Thursday, February 22nd. Cantor Fitzgerald cut their target price on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a report on Wednesday, February 7th. Finally, StockNews.com upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $85.36.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $68.07 on Monday. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The stock’s fifty day simple moving average is $72.79 and its two-hundred day simple moving average is $76.83. Gilead Sciences, Inc. has a 1-year low of $67.62 and a 1-year high of $87.86. The stock has a market cap of $84.75 billion, a PE ratio of 15.13, a price-to-earnings-growth ratio of 0.86 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The business had revenue of $7.12 billion for the quarter, compared to analysts’ expectations of $7.10 billion. During the same period in the prior year, the business earned $1.67 earnings per share. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.08 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Stockholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.52%. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.